Apichope Pharmaceutical Group Co., Ltd. (300723.SZ) Latest Company News

Oct 29, 2026, 09:59 UTC
Yipinhong reported revenue of 617 million yuan, up 381 million yuan in net profit attributable to shareholders, and an adjusted net loss of 243 million yuan for the first three quarters of 2026.
Source:
- finance.sina.cn
Oct 29, 2026, 09:59 UTC
Yipinhong reported third-quarter 2026 revenue of 125 million yuan, down 45.78% year over year, and a net loss attributable to shareholders of 102 million yuan.
Source:
- finance.sina.cn
Oct 8, 2026, 07:52 UTC
China's National Medical Products Administration approved a 25 mg eltrombopag olamine dry suspension made by Yipinhong's wholly owned subsidiary Guangzhou Lianrui Pharmaceutical.
Source:
- finance.sina.cn
Oct 8, 2026, 03:44 UTC
The U.S. Food and Drug Administration approved a clinical trial application for Yipinhong Pharmaceutical’s APH04935 tablets, allowing the study to proceed in the United States under the submitted protocol.
Source:
- finance.sina.cn
Sep 28, 2026, 07:48 UTC
Guangzhou Yipinhong Pharmaceutical, a wholly owned subsidiary of Yipinhong, received a drug registration certificate from China's National Medical Products Administration for fexofenadine hydrochloride oral suspension, allowing it to sell the drug in China.
Source:
- finance.sina.cn
Sep 3, 2026, 09:38 UTC
Yipinhong announced that its gout innovative drug AR882 (deupirtenone) capsules met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia, showing significant efficacy and good safety.
Source:
- finance.sina.cn
Aug 21, 2026, 03:44 UTC
Yipinhong's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed innovative drug APH03867 tablets, intended for treating gout with hyperuricemia.
Source:
- finance.sina.cn
Aug 17, 2026, 09:48 UTC
Yipinhong's subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its innovative drug APH04935, a small-molecule GLP-1R agonist for weight control.
Source:
- finance.sina.cn

300723.SZ

Yipinhong reported revenue of 617 million yuan, up 381 million yuan in net profit attributable to shareholders, and an adjusted net loss of 243 million yuan for the first three quarters of 2026.

Yipinhong reported third-quarter 2026 revenue of 125 million yuan, down 45.78% year over year, and a net loss attributable to shareholders of 102 million yuan.

China's National Medical Products Administration approved a 25 mg eltrombopag olamine dry suspension made by Yipinhong's wholly owned subsidiary Guangzhou Lianrui Pharmaceutical.

The U.S. Food and Drug Administration approved a clinical trial application for Yipinhong Pharmaceutical’s APH04935 tablets, allowing the study to proceed in the United States under the submitted protocol.

Guangzhou Yipinhong Pharmaceutical, a wholly owned subsidiary of Yipinhong, received a drug registration certificate from China's National Medical Products Administration for fexofenadine hydrochloride oral suspension, allowing it to sell the drug in China.

Yipinhong announced that its gout innovative drug AR882 (deupirtenone) capsules met the primary endpoint in a Phase III clinical trial for treating gout with hyperuricemia, showing significant efficacy and good safety.

Yipinhong's wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its self-developed innovative drug APH03867 tablets, intended for treating gout with hyperuricemia.

Yipinhong's subsidiary Guangzhou Yipinhong Pharmaceutical received approval from China's National Medical Products Administration to conduct clinical trials for its innovative drug APH04935, a small-molecule GLP-1R agonist for weight control.